Ketek in CAP / AECB in Ambulatory Adult Patients

NCT00546676 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 174

Last updated 2007-11-14

No results posted yet for this study

Summary

To determine the clinical effectiveness of telithromycin in the treatment of either CAP or AECB in a large population of ambulatory adult patients in a community-based setting.

Conditions

  • Community Acquired Pneumonia (CAP)
  • Acute Exacerbation of Chronic Bronchitis (AECB)

Interventions

DRUG

Telithromycin

Sponsors & Collaborators

Principal Investigators

  • Margaret Mississian · Sanofi

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Completion
2004-12-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00546676 on ClinicalTrials.gov